肿瘤相关淋巴细胞浸润在乳腺癌新辅助化疗疗效评估中的作用被引量：1

下载PDF

导出

摘要目的探讨肿瘤相关淋巴细胞浸润与乳腺癌新辅助化疗疗效之间的关系。方法收集2001年1月至2010年12月共175例在福建省肿瘤医院行新辅助化疗,随后行手术切除的乳腺癌患者,取新辅助化疗前空心针穿刺活检组织标本,用免疫组织化学法检测肿瘤周围组织中的淋巴细胞浸润情况(LI)和CD3+/CD8+的淋巴细胞数量,并分析其与乳腺癌新辅助化疗疗效的关系。结果 19例患者(11%)获得病理完全缓解(PCR)。肿瘤周围组织中的LI、CD3+/CD8+淋巴细胞数量、低临床T分期、HER-2过表达、注射用曲妥珠单抗(赫赛汀)为基础的化疗方案与PCR显著相关。通过多因素分析显示:LI(OR=1.26,P=0.024)、临床T分期(OR=3.06,P=0.041)、注射用曲妥珠单抗(赫赛汀)为基础的化疗方案(OR=4.95,P=0.004)是PCR的独立预测因子。显著的肿瘤相关淋巴细胞浸润和CD3+/CD8+T细胞增多见于下列类型乳腺癌组织中:高组织学分级;淋巴结阳性;激素受体阴性。结论肿瘤相关淋巴细胞浸润程度与PCR显著相关。肿瘤相关淋巴细胞可作为预测乳腺癌新辅助化疗疗效的重要病理因子。

作者曾毅黄凯陈夏

机构地区福建省肿瘤医院

出处《福建医药杂志》 CAS 2014年第3期93-96,共4页 Fujian Medical Journal

关键词乳腺癌淋巴细胞新辅助化疗 T细胞

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Weigel M T,Dowsett M.Current and emerging biomarkers in breast cancer:prognosis and prediction[J].Endocr Relat Cancer,2010,17 (4):R245-262.
2Schnitt S J.Classification and prognosis of invasive breast canc er:from morphology to molecular taxonomy[J].Mod Pathol,2010 (Suppl 2):S60-64.
3Manjili M H,Najarian K,Wang X Y.Signatures of tumor im mune interactions as biomarkers for breast cancer prognosis[J].Future Oncol,2012,8 (6):703-711.
4Sueta A,Yamamoto Y,Hayashi M,et al.Clinical signifi cance of pretherapeutic Ki67 as a predictive parameter for re sponse to neoadjuvant chemotherapy in breast cancer; is it e qually useful across tumor subtypes?[J].Surgery,2014,155(5):927-935.
5Dieci M V,Criscitiello C,Goubar A,et al.Prognostic value of tumor infiltrating lymphocytes on residual disease after pri mary chemotherapy for triple-negative breast cancer:a retro spectivemulticenter study[J].Ann Oncol,2014,25 (3):611-618.
6Menard C,Martin F,Apetoh L,et al.Cancer chemotherapy:not only a direct cytotoxic effect,but also an adjuvant for anti tumor immunity[J].Cancer Immunol Immunother,2008,57(11):1579-1587.
7Banchereau J,Steinman R M.Dendritic cells and the control of immunity[J].Nature,1998,392 (6673):245-252.
8Zitvogel L,Apetoh L,Ghiringhelli F,et al.The anticancer immune response:indispensable for therapeutic success?[J].J Clin Invest,2008,118 (6):1991-2001.
9Soliman H.Developing an effective breast cancer vaccine[J].Cancer Control,2010,17 (3):183-190.
10Alexe G,Dalgin G S,Scanfeld D,et al.High expression of lymphocyte associated genes in node negative HER2 + breast cancers correlates with lower recurrence rates[J].Cancer Res,2007,67 (22):10669-10676.